Trials / Completed
CompletedNCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 338 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2021-05-20
- Primary completion
- 2022-05-16
- Completion
- 2022-11-22
- First posted
- 2021-05-11
- Last updated
- 2023-09-13
- Results posted
- 2023-09-13
Locations
28 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04881760. Inclusion in this directory is not an endorsement.